Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroBo Pharmaceuticals, Inc.

2.36
+0.0000
Volume:- -
Turnover:31.15K
Market Cap:20.33M
PE:-0.55
High:2.36
Open:2.36
Low:2.36
Close:2.36
Loading ...

BRIEF-Neurobo Pharmaceuticals Strategic Realignment Ahead Of Important Clinical Milestones With Name Change To Metavia

Reuters
·
18 Nov 2024

NeuroBo Pharmaceuticals Inc: Common Stock Will Begin Trading on Nasdaq Under "Mtva," Which Is Expected to Be Operative as of November 29

THOMSON REUTERS
·
18 Nov 2024

NeuroBo Pharmaceuticals Inc: Strategic Realignment Ahead of Important Clinical Milestones With Name Change to Metavia

THOMSON REUTERS
·
18 Nov 2024

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

PR Newswire
·
18 Nov 2024

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
15 Nov 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

PR Newswire
·
13 Nov 2024

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024

Zacks Small Cap Research
·
13 Nov 2024

Life Sciences Investor Forum Agenda Announced for November 14th

GlobeNewswire
·
12 Nov 2024

NeuroBo Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

NeuroBo Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.73) Estimate

Benzinga
·
07 Nov 2024

NeuroBo Pharmaceuticals: Cash Was Approximately $21.7 Million as of September 30, 2024

THOMSON REUTERS
·
07 Nov 2024

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
07 Nov 2024

BRIEF-Neurobo Pharmaceuticals Completes Last Patient Last Visit In Its Phase 2A Clinical Trial Evaluating Da-1241 For The Treatment Of Mash

Reuters
·
04 Nov 2024

NeuroBo Pharmaceuticals Inc - Topline Data Readout Expected in December 2024

THOMSON REUTERS
·
04 Nov 2024

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

THOMSON REUTERS
·
04 Nov 2024

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

PR Newswire
·
04 Nov 2024

NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…

Zacks Small Cap Research
·
01 Oct 2024

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

PR Newswire
·
01 Oct 2024

We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate

Simply Wall St.
·
30 Sep 2024

BRIEF-Neurobo Pharmaceuticals Announces Positive Top-Line Data From The SAD Part 1 Of Phase 1 Clinical Trial Evaluating DA-1726

Reuters
·
30 Sep 2024